InspireMD appoints medtech executive Scott R. Ward to Board of Directors

InspireMD, Inc.

Scott R. Ward, former CEO of Cardiovascular Systems and Abbott leader, joins as Class II director.
Ward received options for 16,647 shares and 43,548 restricted stock, vesting on one-year anniversary.
Management highlights Ward's cardiovascular expertise ahead of potential U.S. approval of CGuard Prime.
Ward has over 40 years healthcare experience, including 30 years at Medtronic in senior leadership roles.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott R. Ward

Class II member of the Board

NSPR · InspireMD, Inc.

Effective: 2024-11-25
Filed: November 25, 2024, 6:59 PM ET

On November 25, 2024, the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively) appointed Mr. Scott R. Ward as a Class II member of the Board, effective as of that date, with a term expiring at the Company’s 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Scott R. Ward was appointed as Class II member of the Board at InspireMD, Inc..

Action: appointed
Role: Class II member of the Board

Exact text from the filing

On November 25, 2024, the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively) appointed Mr. Scott R. Ward as a Class II member of the Board, effective as of that date, with a term expiring at the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-047617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.